Infectious Disease Therapeutics
1. Aemcolo patent expiration
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741948 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| US8529945 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| US8263120 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| US8486446 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 16 November, 2022
Market Authorisation Date: 16 November, 2018
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
AEMCOLO family patents
2. Agenerase patent expiration
Treatment: Treatment of hiv infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6730679 | GLAXOSMITHKLINE | Pharmaceutical formulations |
Nov, 2017
(8 years ago) | |
| US5723490 | GLAXOSMITHKLINE | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar, 2015
(10 years ago) | |
| US5646180 | GLAXOSMITHKLINE | Treatment of the CNS effects of HIV |
Jul, 2014
(11 years ago) | |
| US5585397 | GLAXOSMITHKLINE | Sulfonamide inhibitors of aspartyl protease |
Dec, 2013
(12 years ago) | |
Drugs and Companies using AMPRENAVIR ingredient
Market Authorisation Date: 15 April, 1999
Dosage: CAPSULE; SOLUTION
More Information on Dosage
AGENERASE family patents
3. Alinia patent
expiration
Treatment: Method of treating parasitic infections; Method of treating infection by cryptosporidium parvum in an immunocompromised mammal
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968961 | ROMARK | Pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(8 years ago) | |
| US5578621 | ROMARK | Benzamide derivatives |
Sep, 2014
(11 years ago) | |
| US6020353 | ROMARK | 2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide |
Sep, 2014
(11 years ago) | |
| US6117894 | ROMARK | Acid stabilized pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(8 years ago) | |
| US5965590 | ROMARK | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
Jul, 2017
(8 years ago) | |
Drugs and Companies using NITAZOXANIDE ingredient
Market Authorisation Date: 21 July, 2004
Dosage: TABLET; FOR SUSPENSION
More Information on Dosage
ALINIA family patents
4. Apretude patent expiration
Treatment: NA
APRETUDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 months from now) | |
| US8410103 | VIIV | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Feb, 2031
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138264 | VIIV | Pharmaceutical compositions |
Sep, 2031
(5 years from now) | |
| US11224597 | VIIV | Pharmaceutical compositions |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 20 December, 2021
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
APRETUDE family patents
5. Aptivus patent expiration
Treatment: Treatment of hiv-1 infection by the co-administration of tipranavir and ritonavir.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6147095 | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Oct, 2019
(6 years ago) | |
| US6169181 | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
May, 2014
(11 years ago) | |
|
US6169181 (Pediatric) | BOEHRINGER INGELHEIM | Compounds useful to treat retroviral infections |
Nov, 2014
(11 years ago) | |
|
US6147095 (Pediatric) | BOEHRINGER INGELHEIM | Method for improving the pharmacokinetics of tipranavir |
Apr, 2020
(5 years ago) | |
| US6231887 | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jul, 2018
(7 years ago) | |
| US5852195 | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Jun, 2019
(6 years ago) | |
|
US6231887 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jan, 2019
(7 years ago) | |
|
US5852195 (Pediatric) | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Dec, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 23, 2011 |
Drugs and Companies using TIPRANAVIR ingredient
Market Authorisation Date: 23 June, 2008
Dosage: SOLUTION; CAPSULE
More Information on Dosage
APTIVUS family patents
6. Artesunate patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121506 | AMIVAS | Artesunate powders, pharmaceutical compositions and methods of manufacture |
Feb, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2025 |
| Orphan Drug Exclusivity(ODE-290) | May 26, 2027 |
Drugs and Companies using ARTESUNATE ingredient
NCE-1 date: 26 May, 2024
Market Authorisation Date: 26 May, 2020
Dosage: POWDER
More Information on Dosage
ARTESUNATE family patents
7. Avelox patent expiration
Treatment: Method of combating bacteria in a patient
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6610327 | BAYER | Pharmaceutical moxifloxacin preparation |
Oct, 2019
(6 years ago) | |
| US5849752 | BAYER | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(9 years ago) | |
| US5607942 | BAYER | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 December, 1999
Dosage: TABLET
How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage
AVELOX family patents
8. Baraclude patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5206244 (Pediatric) | BRISTOL MYERS | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Aug, 2015
(10 years ago) | |
| US5206244 | BRISTOL MYERS | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Feb, 2015
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-127) | Oct 15, 2013 |
| New Patient Population(NPP) | Oct 12, 2015 |
| Pediatric Exclusivity(PED) | Sep 20, 2017 |
Drugs and Companies using ENTECAVIR ingredient
Market Authorisation Date: 29 March, 2005
Dosage: TABLET; SOLUTION
How can I launch a generic of BARACLUDE before it's drug patent expiration?
More Information on Dosage
BARACLUDE family patents
9. Baxdela patent expiration
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults; Treating an acute bacterial skin and skin structure infection (absssi) in an overwe...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497378 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(3 years from now) | |
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(4 months ago) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(3 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(5 years from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(5 months from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(7 months from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(4 months ago) | |
| US12036219 | MELINTA | Methods of treating infections in overweight and obese patients using antibiotics |
Jun, 2034
(8 years from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US12138257 | MELINTA | Antimicrobial compositions |
May, 2032
(6 years from now) | |
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2021
Market Authorisation Date: 19 June, 2017
Dosage: POWDER; TABLET
More Information on Dosage
BAXDELA family patents
10. Blujepa patent expiration
Treatment: Treatment of adult and pediatric patients 12 years of age and older weighing at least 45 kg who have limited or no alternative options with uncomplicated urogenital gonorrhea caused by susceptible str...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8389524 | GLAXOSMITHKLINE | Tricyclic nitrogen containing compounds as antibacterial agents |
Feb, 2029
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702521 | GLAXOSMITHKLINE | Methods For Treating Neisseria Gonorrhoeae Infection With Substituted 1,2-Dihydro-2A,5,8A-Triazaacenaphthylene-3,8-Diones |
Aug, 2035
(9 years from now) | |
| US11229646 | GLAXOSMITHKLINE | Method For Treating Gonorrhea With (2R)-2-({4-[(3,4-Dihydro-2H-Pyrano[2,3-C]Pyridin-6-Ylmethyl)Amino]-1-Piperidinyl}Methyl)-1,2-Dihydro-3H,8H-2A,5,8A-Triazaacenaphthylene-3,8-Dione |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-978) | Dec 11, 2028 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 25, 2035 |
Drugs and Companies using GEPOTIDACIN MESYLATE ingredient
NCE-1 date: 25 March, 2029
Market Authorisation Date: 25 March, 2025
Dosage: TABLET
More Information on Dosage
BLUJEPA family patents
11. Brexafemme patent expiration
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...
BREXAFEMME's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188085 | GLAXOSMITHKLINE | Antifungal agents |
Aug, 2030
(4 years from now) | |
| US10927142 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(8 years from now) | |
| US10174074 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(8 years from now) | |
| US11534433 | GLAXOSMITHKLINE | Antifungal agents with enhanced activity in acidic pH |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-903) | Nov 30, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2025
Market Authorisation Date: 01 June, 2021
Dosage: TABLET
More Information on Dosage
BREXAFEMME family patents
12. Cancidas patent expiration
Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(11 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(10 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Dosage: POWDER
How can I launch a generic of CANCIDAS before it's drug patent expiration?
More Information on Dosage
CANCIDAS family patents
13. Cresemba patent expiration
Treatment: NA
CRESEMBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459561 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2020
(5 years ago) | |
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(3 months ago) | |
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(1 year, 6 months from now) | |
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(1 year, 6 months from now) | |
|
US6812238 (Pediatric) | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Apr, 2026
(2 months from now) | |
|
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(2 years from now) | |
|
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 07 March, 2019
Market Authorisation Date: 06 March, 2015
Dosage: POWDER; CAPSULE
How can I launch a generic of CRESEMBA before it's drug patent expiration?
More Information on Dosage
CRESEMBA family patents
14. Cubicin patent expiration
Treatment: Method of treating bacterial infections; Method for treating bacterial infection; Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloods...
CUBICIN's oppositions filed in EPO
CUBICIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST | Lipopeptide compositions and related methods |
Nov, 2030
(4 years from now) | |
| US6468967 | CUBIST | Methods for administration of antibiotics |
Sep, 2019
(6 years ago) | |
| US8058238 | CUBIST | High purity lipopeptides |
Nov, 2020
(5 years ago) | |
| US6852689 | CUBIST | Methods for administration of antibiotics |
Sep, 2019
(6 years ago) | |
| US8129342 | CUBIST | High purity lipopeptides |
Nov, 2020
(5 years ago) | |
| USRE39071 | CUBIST | Anhydro-and isomer-a-21978c cyclic peptides |
Jun, 2016
(9 years ago) | |
| US8003673 | CUBIST | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 29, 2020 |
| M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Dosage: POWDER
How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage
CUBICIN family patents
15. Daklinza patent expiration
Treatment: Method of inhibiting hepatitis c virus; Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity
DAKLINZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL MYERS | Hepatitis C virus inhibitors |
Aug, 2027
(1 year, 5 months from now) | |
| US8629171 | BRISTOL MYERS | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
Jun, 2031
(5 years from now) | |
| US8642025 | BRISTOL MYERS | Hepatitis C virus inhibitors |
Aug, 2027
(1 year, 5 months from now) | |
| US8329159 | BRISTOL MYERS | Hepatitis C virus inhibitors |
Jul, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL MYERS | Hepatitis C virus inhibitors |
Aug, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Indication(I-727) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Dosage: TABLET
More Information on Dosage
DAKLINZA family patents
16. Dificid patent expiration
Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8586551 | CUBIST | 18-membered macrocycles and analogs thereof |
Jul, 2023
(2 years ago) | |
| US7378508 | CUBIST | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(1 year, 5 months from now) | |
| US7863249 | CUBIST | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859510 | CUBIST | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(1 year, 5 months from now) | |
| US7906489 | CUBIST | 18-membered macrocycles and analogs thereof |
Mar, 2027
(1 year, 10 days from now) | |
|
US8586551 (Pediatric) | CUBIST | 18-membered macrocycles and analogs thereof |
Jan, 2024
(2 years ago) | |
| US7863249 | CUBIST | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(1 year, 5 months from now) | |
| US9808530 | CUBIST | Composition of tiacumicin compounds |
May, 2034
(8 years from now) | |
|
US7378508 (Pediatric) | CUBIST | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(1 year, 11 months from now) | |
|
US7863249 (Pediatric) | CUBIST | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(1 year, 11 months from now) | |
|
US7906489 (Pediatric) | CUBIST | 18-membered macrocycles and analogs thereof |
Sep, 2027
(1 year, 6 months from now) | |
|
US8859510 (Pediatric) | CUBIST | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(1 year, 11 months from now) | |
|
US9808530 (Pediatric) | CUBIST | Composition of tiacumicin compounds |
Nov, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
| New Product(NP) | Jan 24, 2023 |
| New Patient Population(NPP) | Jan 24, 2023 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage
DIFICID family patents
17. Doribax patent expiration
Treatment: Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247402 | SHIONOGI | Crystal form of pyrrolidylthiocarbapenem derivative |
Mar, 2021
(4 years ago) | |
| US5317016 | SHIONOGI | Pyrrolidylthiocarbapenem derivative |
Jun, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using DORIPENEM ingredient
NCE-1 date: 13 October, 2011
Market Authorisation Date: 05 October, 2010
Dosage: INJECTABLE
How can I launch a generic of DORIBAX before it's drug patent expiration?
More Information on Dosage
DORIBAX family patents
18. Edurant patent expiration
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
EDURANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7638522 | JANSSEN | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(2 years ago) | |
|
US7125879 (Pediatric) | JANSSEN | HIV inhibiting pyrimidines derivatives |
Oct, 2025
(4 months ago) | |
| US7067522 | JANSSEN | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(6 years ago) | |
| US8101629 | JANSSEN | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(3 years ago) | |
| US8080551 | JANSSEN | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(2 years ago) | |
| US6838464 | JANSSEN | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| M(M-223) | Feb 01, 2021 |
| New Patient Population(NPP) | Mar 15, 2027 |
| Pediatric Exclusivity(PED) | Sep 15, 2027 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 21 May, 2015
Market Authorisation Date: 20 May, 2011
Dosage: TABLET
More Information on Dosage
EDURANT family patents
19. Emtriva patent expiration
Treatment: Treatment of hiv infection
EMTRIVA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(9 years ago) | |
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(10 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(4 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(4 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(5 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(8 years ago) | |
Drugs and Companies using EMTRICITABINE ingredient
Market Authorisation Date: 28 September, 2005
Dosage: SOLUTION; CAPSULE
How can I launch a generic of EMTRIVA before it's drug patent expiration?
More Information on Dosage
EMTRIVA family patents
20. Eraxis patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965525 | VICURON | Cyclic peptide antifungal agents |
Feb, 2020
(6 years ago) | |
| US7709444 | VICURON | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| US6960564 | VICURON | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
Drugs and Companies using ANIDULAFUNGIN ingredient
Market Authorisation Date: 17 February, 2006
Dosage: POWDER
More Information on Dosage
ERAXIS family patents
21. Factive patent expiration
Treatment: Method of treating bacterial infections; Use of quinolone compounds against anaerobic pathogenic bacteria; Use of quinolone compounds against pneumococcal pathogenic bacteria; Use of quinolone compoun...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962468 | LG CHEM | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Jun, 2015
(10 years ago) | |
| US6455540 | LG CHEM | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5633262 | LG CHEM | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Jun, 2015
(10 years ago) | |
| US6803376 | LG CHEM | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(6 years ago) | |
| US6340689 | LG CHEM | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5776944 | LG CHEM | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Apr, 2017
(8 years ago) | |
| US6723734 | LG CHEM | Salt of naphthyridine carboxylic acid derivative |
Mar, 2018
(7 years ago) | |
| US6331550 | LG CHEM | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US6262071 | LG CHEM | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
Sep, 2019
(6 years ago) | |
Drugs and Companies using GEMIFLOXACIN MESYLATE ingredient
Market Authorisation Date: 04 April, 2003
Dosage: TABLET
How can I launch a generic of FACTIVE before it's drug patent expiration?
More Information on Dosage
FACTIVE family patents
22. Fetroja patent expiration
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI | Cephalosporin having catechol group |
Nov, 2033
(7 years from now) | |
| US10004750 | SHIONOGI | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Dosage: POWDER
More Information on Dosage
FETROJA family patents
23. Fuzeon patent expiration
Treatment: Treatment of hiv
FUZEON IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6133418 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Nov, 2014
(11 years ago) | |
| US6475491 | ROCHE | Treatment of HIV and other viral infections using combinatorial therapy |
Jun, 2015
(10 years ago) | |
| US5464933 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Jun, 2013
(12 years ago) | |
Drugs and Companies using ENFUVIRTIDE ingredient
Market Authorisation Date: 13 March, 2003
Dosage: INJECTABLE
More Information on Dosage
FUZEON family patents
24. Hepsera patent expiration
Treatment: Therapy in chronic hepatitis b virus infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5663159 | GILEAD | Prodrugs of phosphonates |
Sep, 2014
(11 years ago) | |
| US6451340 | GILEAD | Nucleotide analog compositions |
Jul, 2018
(7 years ago) | |
Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient
Market Authorisation Date: 20 September, 2002
Dosage: TABLET
How can I launch a generic of HEPSERA before it's drug patent expiration?
More Information on Dosage
HEPSERA family patents
25. Incivek patent expiration
Treatment: Method of treating chronic hepatitis c
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX | Peptidomimetic protease inhibitors |
Feb, 2025
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX | Dose forms |
May, 2028
(2 years from now) | |
| US8529882 | VERTEX | Peptidomimetic protease inhibitors |
Aug, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2016 |
Drugs and Companies using TELAPREVIR ingredient
NCE-1 date: 24 May, 2015
Market Authorisation Date: 23 May, 2011
Dosage: TABLET
More Information on Dosage
INCIVEK family patents
26. Intelence patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7887845 | JANSSEN | Antiviral compositions |
Mar, 2019
(6 years ago) | |
|
US6878717 (Pediatric) | JANSSEN | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
| US6878717 | JANSSEN | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US8003789 | JANSSEN | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US7037917 | JANSSEN | HIV replication inhibiting pyrimidines |
Dec, 2020
(5 years ago) | |
|
US7037917 (Pediatric) | JANSSEN | HIV replication inhibiting pyrimidines |
Jun, 2021
(4 years ago) | |
|
US8003789 (Pediatric) | JANSSEN | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
|
US7887845 (Pediatric) | JANSSEN | Antiviral compositions |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
| New Patient Population(NPP) | Mar 26, 2015 |
| Pediatric Exclusivity(PED) | Jan 16, 2022 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Dosage: TABLET
More Information on Dosage
INTELENCE family patents
27. Invanz patent expiration
Treatment: Treatment of bacterial infectious disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5478820 (Pediatric) | MERCK | Antibiotic compounds |
May, 2016
(9 years ago) | |
| US5652233 | MERCK | Antibiotic compounds |
Feb, 2013
(13 years ago) | |
|
US5952323 (Pediatric) | MERCK | Carbapenem antibiotic |
Nov, 2017
(8 years ago) | |
| US7342005 | MERCK | Antibiotic compounds |
Feb, 2013
(13 years ago) | |
|
US7342005 (Pediatric) | MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
|
US5652233 (Pediatric) | MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
| US5478820 | MERCK | Antibiotic compounds |
Nov, 2015
(10 years ago) | |
| US5952323 | MERCK | Carbapenem antibiotic |
May, 2017
(8 years ago) | |
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Dosage: INJECTABLE
How can I launch a generic of INVANZ before it's drug patent expiration?
More Information on Dosage
INVANZ family patents
28. Isentress patent expiration
Treatment: Treatment of hiv infection
ISENTRESS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
| US8852632 | MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(1 year, 11 months from now) | |
| US8771733 | MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(4 years from now) | |
| US7754731 | MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
| US7435734 | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
|
US7217713 (Pediatric) | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
| US7169780 | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
|
US7435734 (Pediatric) | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
|
US7169780 (Pediatric) | MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 10 months ago) | |
|
US7754731 (Pediatric) | MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Dosage: TABLET, CHEWABLE; POWDER; TABLET
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
29. Ketek patent expiration
Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USD459798 | SANOFI | Pill tablet |
Sep, 2015
(10 years ago) | |
| US5635485 | SANOFI | Erythromycin compounds |
Apr, 2018
(7 years ago) | |
Drugs and Companies using TELITHROMYCIN ingredient
Market Authorisation Date: 09 February, 2005
Dosage: TABLET
More Information on Dosage
KETEK family patents
30. Livtencity patent expiration
Treatment: Treating post-transplant cmv infection/disease refractory to ganciclovir, valganciclovir, cidofovir or foscarnet by administering 1200 mg maribavir twice daily, where the patient is concomitantly expo...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12295940 | TAKEDA | Viral inhibitors, the synthesis thereof, and intermediates thereto |
Oct, 2043
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12213989 | TAKEDA | Use of maribavir in treatment regimens |
Nov, 2042
(16 years from now) | |
| US11684632 | TAKEDA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(5 years from now) | |
| US12447170 | TAKEDA | Use Of Maribavir In Treatment Regimens |
Nov, 2042
(16 years from now) | |
| US12433907 | TAKEDA | Use Of Maribavir In Treatment Regimens |
Nov, 2042
(16 years from now) | |
| US12447169 | TAKEDA | Maribavir Isomers, Compositions, Methods Of Making And Methods Of Using |
Oct, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Dosage: TABLET
How can I launch a generic of LIVTENCITY before it's drug patent expiration?
More Information on Dosage
LIVTENCITY family patents
31. Mycamine patent expiration
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients; Treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6265536 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Sep, 2015
(10 years ago) | |
| US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(6 years ago) | |
|
US6774104 (Pediatric) | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jul, 2021
(4 years ago) | |
| US6774104 | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jan, 2021
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-821) | Dec 20, 2022 |
| Pediatric Exclusivity(PED) | Jun 20, 2023 |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 16 March, 2005
Dosage: INJECTABLE
How can I launch a generic of MYCAMINE before it's drug patent expiration?
More Information on Dosage
MYCAMINE family patents
32. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
NOXAFIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703079 | MERCK | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| US5661151 | MERCK | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | MERCK | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MERCK | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US9023790 | MERCK | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(5 years from now) | |
| US8410077 | MERCK | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9358297 | MERCK | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(5 years from now) | |
| US10117951 | MERCK | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Dosage: SOLUTION; TABLET, DELAYED RELEASE
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
33. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(3 years ago) | |
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Dosage: SUSPENSION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
34. Nuzyra patent expiration
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of community acquired bacterial pneumonia; Treatment of bacterial skin and skin structure infection; Treatment of subjects having b...
NUZYRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(2 years ago) | |
| US7553828 | PARATEK | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(8 months ago) | |
| US8383610 | PARATEK | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(4 years ago) | |
| US10383884 | PARATEK | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9724358 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10124014 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10111890 | PARATEK | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(11 years from now) | |
| US10835542 | PARATEK | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9265740 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US9314475 | PARATEK | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 02 October, 2022
Market Authorisation Date: 02 October, 2018
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
35. Olumiant patent expiration
Treatment: Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical vent...
OLUMIANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY | Azetidine and cyclobutane derivatives as JAK inhibitors |
May, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737469 | ELI LILLY | Methods for treating hair loss disorders |
Nov, 2031
(5 years from now) | |
| US9089574 | ELI LILLY | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(6 years from now) | |
| US8420629 | ELI LILLY | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(3 years from now) | |
| US11045474 | ELI LILLY | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(6 years from now) | |
| US11806555 | ELI LILLY | Methods for treating hair loss disorders |
Nov, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
| New Indication(I-891) | May 10, 2025 |
| New Indication(I-890) | Jun 13, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Dosage: TABLET
How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage
OLUMIANT family patents
36. Olysio patent expiration
Treatment: Method of treating hepatitis c
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8349869 | JANSSEN | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| US8754106 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| US8741926 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| US9040562 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| US8148399 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(3 years from now) | |
| US9856265 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| US7671032 | JANSSEN | HCV NS-3 serine protease inhibitors |
May, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9353103 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| US9623022 | JANSSEN | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| New Indication(I-717) | Oct 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
| M(M-179) | May 20, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Dosage: CAPSULE
More Information on Dosage
OLYSIO family patents
37. Orbactiv patent expiration
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections; Treatment of acute bacterial skin and skin structure infection...
ORBACTIV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5840684 | MELINTA | Glycopeptide antibiotic derivatives |
Nov, 2020
(5 years ago) | |
| US5998581 | MELINTA | Reductive alkylation of glycopeptide antibiotics |
Nov, 2017
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA | Methods of treatment using single doses of oritavancin |
Aug, 2029
(3 years from now) | |
| US9682061 | MELINTA | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(4 years from now) | |
| US9649352 | MELINTA | High purity oritavancin and method of producing same |
Jul, 2035
(9 years from now) | |
| US12514899 | MELINTA | Methods Of Treatment Using Single Doses Of Oritavancin |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Dosage: POWDER
More Information on Dosage
ORBACTIV family patents
38. Pifeltro patent expiration
Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MERCK | Non-nucleoside reverse transcriptase inhibitors |
Aug, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-827) | Sep 19, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
| New Patient Population(NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE ingredient
NCE-1 date: 30 August, 2022
Market Authorisation Date: 30 August, 2018
Dosage: TABLET
More Information on Dosage
PIFELTRO family patents
39. Prevymis patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7196086 | MERCK | Substituted dihydroquinazolines |
May, 2024
(1 year, 9 months ago) | |
| US8513255 | MERCK | Substituted dihydroquinazolines |
May, 2024
(1 year, 9 months ago) | |
| USRE46791 | MERCK | Substituted dihydroquinazolines |
Jan, 2029
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| New Product(NP) | Aug 30, 2027 |
| New Patient Population(NPP) | Aug 30, 2027 |
| ODE*(ODE*) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-495) | Aug 30, 2031 |
| Orphan Drug Exclusivity(ODE-497) | Aug 30, 2031 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Dosage: TABLET; SOLUTION; PELLETS
More Information on Dosage
PREVYMIS family patents
40. Rapivab patent expiration
Treatment: Treatment of acute uncomplicated influenza in patients 6 months and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6503745 | BIOCRYST | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov, 2019
(6 years ago) | |
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(11 months from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Patient Population(NPP) | Sep 20, 2020 |
Drugs and Companies using PERAMIVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Dosage: SOLUTION
More Information on Dosage
RAPIVAB family patents
41. Rebetol patent expiration
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(2 years ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(2 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Dosage: SOLUTION
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
42. Rebetol patent expiration
Treatment: Method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin; Me...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6177074 (Pediatric) | MERCK | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
|
US6524570 (Pediatric) | MERCK | Polyethylene glycol modified interferon therapy |
May, 2017
(8 years ago) | |
| US6472373 | MERCK | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6172046 | MERCK | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(8 years ago) | |
| US6461605 | MERCK | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(9 years ago) | |
|
US6172046 (Pediatric) | MERCK | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6177074 | MERCK | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6472373 (Pediatric) | MERCK | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(7 years ago) | |
| US6524570 | MERCK | Polyethylene glycol modified interferon therapy |
Nov, 2016
(9 years ago) | |
|
US6461605 (Pediatric) | MERCK | Continuous low-dose cytokine infusion therapy |
May, 2017
(8 years ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Dosage: CAPSULE
How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage
REBETOL family patents
43. Relenza patent expiration
Treatment: Prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360817 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(12 years ago) | |
| US6294572 | GLAXOSMITHKLINE | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(11 years ago) | |
| US5648379 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(11 years ago) | |
Drugs and Companies using ZANAMIVIR ingredient
Market Authorisation Date: 26 July, 1999
Dosage: POWDER
More Information on Dosage
RELENZA family patents
44. Reyataz patent expiration
Treatment: Method for treating hiv-1 infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849911 | BRISTOL MYERS | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849911 | BRISTOL MYERS | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
|
US5849911 (Pediatric) | BRISTOL MYERS | Antivirally active heterocyclic azahexane derivatives |
Dec, 2017
(8 years ago) | |
|
US6087383 (Pediatric) | BRISTOL MYERS | Bisulfate salt of HIV protease inhibitor |
Jun, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-116) | Sep 30, 2011 |
| New Dosing Schedule(D-130) | Feb 04, 2014 |
| New Product(NP) | Jun 02, 2017 |
| New Patient Population(NPP) | Sep 24, 2018 |
| Pediatric Exclusivity(PED) | Mar 24, 2019 |
Drugs and Companies using ATAZANAVIR SULFATE ingredient
Market Authorisation Date: 20 June, 2003
Dosage: CAPSULE; POWDER
How can I launch a generic of REYATAZ before it's drug patent expiration?
More Information on Dosage
REYATAZ family patents
45. Rezzayo patent expiration
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11654196 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2032
(6 years from now) | |
| US10702573 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US9526835 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US8722619 | MUNDIPHARMA | Antifungal agents and uses thereof |
Mar, 2032
(6 years from now) | |
| US11197909 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| US11819533 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712459 | MUNDIPHARMA | Dosing regimens for treatment of fungal infections |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 23 March, 2027
Market Authorisation Date: 22 March, 2023
Dosage: POWDER
More Information on Dosage
REZZAYO family patents
46. Rukobia patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461333 | VIIV | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(11 months ago) | |
| US7745625 | VIIV | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168615 | VIIV | Prodrugs of piperazine and substituted piperidine antiviral agents |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RUKOBIA family patents
47. Selzentry patent expiration
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6667314 | VIIV | Tropane derivatives useful in therapy |
Aug, 2021
(4 years ago) | |
| US6586430 | VIIV | CCR5 modulators |
Dec, 2019
(6 years ago) | |
| US7576097 | VIIV | Tropane derivatives useful in therapy |
May, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6667314 | VIIV | Tropane derivatives useful in therapy |
Aug, 2021
(4 years ago) | |
|
US7576097 (Pediatric) | VIIV | Tropane derivatives useful in therapy |
Nov, 2021
(4 years ago) | |
|
US7368460 (Pediatric) | VIIV | Tropane derivatives useful in therapy |
May, 2023
(2 years ago) | |
| US6586430 | VIIV | CCR5 modulators |
Dec, 2019
(6 years ago) | |
| US7368460 | VIIV | Tropane derivatives useful in therapy |
Nov, 2022
(3 years ago) | |
| US7576097 | VIIV | Tropane derivatives useful in therapy |
May, 2021
(4 years ago) | |
|
US6667314 (Pediatric) | VIIV | Tropane derivatives useful in therapy |
Feb, 2022
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2012 |
| New Patient Population(NPP) | Oct 30, 2023 |
| New Product(NP) | Nov 04, 2019 |
| New Strength(NS) | Nov 04, 2019 |
| Pediatric Exclusivity(PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
NCE-1 date: 07 August, 2011
Market Authorisation Date: 04 November, 2016
Dosage: TABLET; SOLUTION
How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage
SELZENTRY family patents
48. Sirturo patent expiration
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
SIRTURO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546428 | JANSSEN | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Mar, 2029
(3 years from now) | |
| US7498343 | JANSSEN | Mycobacterial inhibitors |
Dec, 2026
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 28, 2019 |
| Orphan Drug Exclusivity(ODE-38) | Dec 28, 2019 |
| New Patient Population(NPP) | Aug 09, 2022 |
| ODE*(ODE*) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-251) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-307) | May 27, 2027 |
| M(M-306) | Jun 21, 2027 |
Drugs and Companies using BEDAQUILINE FUMARATE ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 27 May, 2020
Dosage: TABLET
More Information on Dosage
SIRTURO family patents
49. Sivextro patent expiration
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8426389 | CUBIST | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(4 years from now) | |
| US8420676 | CUBIST | Oxazolidinone derivatives |
Feb, 2028
(2 years from now) | |
| US9624250 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| US7816379 | CUBIST | Oxazolidinone derivatives |
Jun, 2028
(2 years from now) | |
| US10442829 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9988406 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| US10065947 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
| New Patient Population(NPP) | Apr 04, 2028 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 20 June, 2018
Market Authorisation Date: 20 June, 2014
Dosage: TABLET; POWDER
More Information on Dosage
SIVEXTRO family patents
50. Solosec patent expiration
Treatment: Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12280037 | EVOFEM | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Dec, 2041
(15 years from now) | |
| US10849884 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US10857133 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11324721 | EVOFEM | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(9 years from now) | |
| US10335390 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11602522 | EVOFEM | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(9 years from now) | |
| US11000508 | EVOFEM | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(9 years from now) | |
| US11000507 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11020377 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US10682338 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11684607 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2022 |
| New Indication(I-866) | Jun 30, 2024 |
| New Patient Population(NPP) | Jan 26, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 15 September, 2021
Market Authorisation Date: 15 September, 2017
Dosage: GRANULE
More Information on Dosage
SOLOSEC family patents
51. Sovaldi patent expiration
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD | NA |
Mar, 2028
(2 years from now) | |
| US8334270 | GILEAD | NA |
Mar, 2028
(2 years from now) | |
| US8580765 | GILEAD | NA |
Mar, 2028
(2 years from now) | |
| US7964580 | GILEAD | NA |
Mar, 2029
(3 years from now) | |
| US8618076 | GILEAD | Nucleoside phosphoramidates |
Dec, 2030
(4 years from now) | |
| US9284342 | GILEAD | Nucleoside phosphoramidates |
Sep, 2030
(4 years from now) | |
| US8633309 | GILEAD | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8633309 (Pediatric) | GILEAD | Nucleoside phosphoramidates |
Sep, 2029
(3 years from now) | |
| US8889159 | GILEAD | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| US9549941 | GILEAD | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD | NA |
Sep, 2028
(2 years from now) | |
|
US8580765 (Pediatric) | GILEAD | NA |
Sep, 2028
(2 years from now) | |
|
US7964580 (Pediatric) | GILEAD | NA |
Sep, 2029
(3 years from now) | |
|
US8618076 (Pediatric) | GILEAD | Nucleoside phosphoramidates |
Jun, 2031
(5 years from now) | |
|
US8889159 (Pediatric) | GILEAD | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD | NA |
Sep, 2028
(2 years from now) | |
|
US9284342 (Pediatric) | GILEAD | Nucleoside phosphoramidates |
Mar, 2031
(5 years from now) | |
|
US9549941 (Pediatric) | GILEAD | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Dosage: PELLETS; TABLET
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
52. Spectracef patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958915 | VANSEN | Antibacterial composition for oral administration |
Oct, 2016
(9 years ago) | |
Drugs and Companies using CEFDITOREN PIVOXIL ingredient
Market Authorisation Date: 29 August, 2001
Dosage: TABLET
More Information on Dosage
SPECTRACEF family patents
53. Sunlenca patent expiration
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD | Therapeutic compounds |
Feb, 2034
(8 years from now) | |
| US11267799 | GILEAD | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(12 years from now) | |
| US10071985 | GILEAD | Therapeutic compounds |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD | Therapeutic compounds |
Aug, 2037
(11 years from now) | |
| US11944611 | GILEAD | Capsid inhibitors for the treatment of HIV |
Aug, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Dosage: SOLUTION; TABLET
More Information on Dosage
SUNLENCA family patents
54. Tamiflu patent expiration
Treatment: Treatment and prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5952375 | ROCHE | Compounds and methods for synthesis and therapy |
Feb, 2015
(10 years ago) | |
| US5763483 | ROCHE | Carbocyclic compounds |
Dec, 2016
(9 years ago) | |
| US5866601 | ROCHE | Carbocyclic compounds |
Feb, 2016
(10 years ago) | |
|
US5952375 (Pediatric) | ROCHE | Compounds and methods for synthesis and therapy |
Aug, 2015
(10 years ago) | |
|
US5763483 (Pediatric) | ROCHE | Carbocyclic compounds |
Jun, 2017
(8 years ago) | |
|
US5866601 (Pediatric) | ROCHE | Carbocyclic compounds |
Aug, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-90) | Feb 22, 2013 |
| New Patient Population(NPP) | Dec 21, 2015 |
| M(M-251) | Aug 02, 2022 |
Drugs and Companies using OSELTAMIVIR PHOSPHATE ingredient
Market Authorisation Date: 02 July, 2007
Dosage: CAPSULE; FOR SUSPENSION
How can I launch a generic of TAMIFLU before it's drug patent expiration?
More Information on Dosage
TAMIFLU family patents
55. Tivicay patent expiration
Treatment: NA
TIVICAY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(1 year, 7 months from now) | |
| US9242986 | VIIV | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(2 years from now) | |
|
US9242986 (Pediatric) | VIIV | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-166) | Jul 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Indication(I-758) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Dosage: TABLET
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
56. Tygacil patent expiration
Treatment: Method of treating bacterial infections
TYGACIL's oppositions filed in EPO
TYGACIL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40183 | PF PRISM CV | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
Apr, 2016
(9 years ago) | |
| USRE40086 | PF PRISM CV | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
Jun, 2013
(12 years ago) | |
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(2 years from now) | |
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(19 days from now) | |
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(2 years from now) | |
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(4 years from now) | |
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(19 days from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(19 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Dosage: POWDER
More Information on Dosage
TYGACIL family patents
57. Tyzeka patent expiration
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotra...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(2 years ago) | |
| US6569837 | NOVARTIS | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
Oct, 2020
(5 years ago) | |
| US7795238 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6566344 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6444652 | NOVARTIS | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6395716 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2011 |
| M(M-124) | Jan 28, 2016 |
Drugs and Companies using TELBIVUDINE ingredient
NCE-1 date: 25 October, 2010
Market Authorisation Date: 25 October, 2006
Dosage: TABLET; SOLUTION
More Information on Dosage
TYZEKA family patents
58. Veklury patent expiration
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (birth to < 18 years of age weighing > 1.5 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9949994 | GILEAD | Methods for treating Filoviridae virus infections |
Oct, 2035
(9 years from now) | |
| US11492353 | GILEAD | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(5 years from now) | |
| US8318682 | GILEAD | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US8008264 | GILEAD | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(3 years from now) | |
| USRE46762 | GILEAD | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US9724360 | GILEAD | Methods for treating Filoviridae virus infections |
Oct, 2035
(9 years from now) | |
| US10065958 | GILEAD | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11266681 | GILEAD | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
| US10675296 | GILEAD | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
|
US11903953 (Pediatric) | GILEAD | Remdesivir treatment methods |
Nov, 2041
(15 years from now) | |
|
US10675296 (Pediatric) | GILEAD | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(12 years from now) | |
|
US11266681 (Pediatric) | GILEAD | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(12 years from now) | |
| US10695361 | GILEAD | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(10 years from now) | |
| US11975012 | GILEAD | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11382926 | GILEAD | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(10 years from now) | |
| US11007208 | GILEAD | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(10 years from now) | |
| US11903953 | GILEAD | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11491169 | GILEAD | Remdesivir treatment methods |
May, 2041
(15 years from now) | |
| US11975017 | GILEAD | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(12 years from now) | |
|
US11492353 (Pediatric) | GILEAD | Methods and compounds for treating Paramyxoviridae virus infections |
Jun, 2032
(6 years from now) | |
|
US11491169 (Pediatric) | GILEAD | Remdesivir treatment methods |
Nov, 2041
(15 years from now) | |
|
US11007208 (Pediatric) | GILEAD | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
US11382926 (Pediatric) | GILEAD | Methods for treating Arenaviridae and Coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
US9949994 (Pediatric) | GILEAD | Methods for treating Filoviridae virus infections |
Apr, 2036
(10 years from now) | |
|
US8008264 (Pediatric) | GILEAD | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Mar, 2030
(4 years from now) | |
|
US8318682 (Pediatric) | GILEAD | 1′substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(3 years from now) | |
|
US10065958 (Pediatric) | GILEAD | Methods and compounds for treating Paramyxoviridae virus infections |
Mar, 2032
(6 years from now) | |
|
US10695361 (Pediatric) | GILEAD | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(11 years from now) | |
|
USRE46762 (Pediatric) | GILEAD | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(3 years from now) | |
|
US9724360 (Pediatric) | GILEAD | Methods for treating Filoviridae virus infections |
Apr, 2036
(10 years from now) | |
|
US11975017 (Pediatric) | GILEAD | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(12 years from now) | |
|
US11975012 (Pediatric) | GILEAD | Remdesivir treatment methods |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 22 October, 2024
Market Authorisation Date: 22 October, 2020
Dosage: SOLUTION; POWDER
How can I launch a generic of VEKLURY before it's drug patent expiration?
More Information on Dosage
VEKLURY family patents
59. Vfend patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5567817 | PF PRISM CV | Triazole antifungal agents |
May, 2016
(9 years ago) | |
| US6632803 | PF PRISM CV | Pharmaceutical formulations containing voriconazole |
Jun, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 29, 2022 |
Drugs and Companies using VORICONAZOLE ingredient
Market Authorisation Date: 24 May, 2002
Dosage: TABLET; POWDER; FOR SUSPENSION
How can I launch a generic of VFEND before it's drug patent expiration?
More Information on Dosage
VFEND family patents
60. Vibativ patent expiration
Treatment: Method for treating bacterial infection; Method of treating a staphylococcal infection; Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7544364 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(4 years ago) | |
| US6872701 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Jun, 2021
(4 years ago) | |
| US8158580 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(4 years ago) | |
| US6635618 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Sep, 2023
(2 years ago) | |
| US7008923 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US7700550 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US7208471 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US8101575 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US6858584 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(3 years ago) | |
| US7351691 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
| New Indication(I-673) | Jun 21, 2016 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Dosage: POWDER
More Information on Dosage
VIBATIV family patents
61. Victrelis patent expiration
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease; Treatment of chro...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772178 | MERCK | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(1 year, 8 months from now) | |
| US8119602 | MERCK | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(1 year, 23 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Dosage: CAPSULE
More Information on Dosage
VICTRELIS family patents
62. Viread patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hiv; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and olde...
VIREAD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(8 years ago) | |
|
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(8 years ago) | |
|
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(8 years ago) | |
|
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(8 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(8 years ago) | |
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(8 years ago) | |
| US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-569) | Aug 11, 2011 |
| New Patient Population(NPP) | Aug 16, 2015 |
| Pediatric Exclusivity(PED) | Sep 24, 2017 |
| M(M-95) | Oct 01, 2013 |
| New Dosage Form(NDF) | Jan 18, 2015 |
| M(M-128) | Jul 24, 2016 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Dosage: POWDER; TABLET
How can I launch a generic of VIREAD before it's drug patent expiration?
More Information on Dosage
VIREAD family patents
63. Vivjoa patent expiration
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236962 | MYCOVIA | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| US9840492 | MYCOVIA | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| US10414751 | MYCOVIA | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754227 | MYCOVIA | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| US11247981 | MYCOVIA | Metalloenzyme inhibitor compounds |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 26 April, 2026
Market Authorisation Date: 26 April, 2022
Dosage: CAPSULE
More Information on Dosage
VIVJOA family patents
64. Vocabria patent expiration
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
VOCABRIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Feb, 2031
(4 years from now) | |
| US10927129 | VIIV | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-273) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Dosage: TABLET
More Information on Dosage
VOCABRIA family patents
65. Xenleta patent expiration
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | HONG KONG | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(4 years ago) | |
| US8071643 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2033
(7 years from now) | |
| US8153689 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(2 years from now) | |
| US9120727 | HONG KONG | Process for the preparation of pleuromutilins |
May, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121582 | HONG KONG | Injectable pharmaceutical formulations of lefamulin |
Jun, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 20 August, 2023
Market Authorisation Date: 19 August, 2019
Dosage: TABLET; SOLUTION
More Information on Dosage
XENLETA family patents
66. Xifaxan patent expiration
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; ...
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741904 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US8835452 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US8193196 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 6 months from now) | |
| US8158781 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7612199 | SALIX | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7902206 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7045620 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 8 months ago) | |
| US7906542 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456384 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US10335397 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9421195 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8946252 | SALIX | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7452857 | SALIX | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8829017 | SALIX | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8642573 | SALIX | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US10314828 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7915275 | SALIX | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(11 months ago) | |
| US7605240 | SALIX | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US7935799 | SALIX | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US10709694 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US10765667 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US8969398 | SALIX | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US6861053 | SALIX | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8518949 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US9629828 | SALIX | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9271968 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US8158781 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US8158644 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7612199 | SALIX | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US8853231 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7045620 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 8 months ago) | |
| US8193196 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 6 months from now) | |
| US10703763 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US7718608 | SALIX | Methods of treating a subject suffering from irritable bowel syndrome |
Aug, 2019
(6 years ago) | |
| US8309569 | SALIX | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(3 years from now) | |
| US7902206 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7906542 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(8 months ago) | |
| US11564912 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US7928115 | SALIX | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US11779571 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
67. Xofluza patent expiration
Treatment: Method for post-exposure prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10759814 | GENENTECH | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(11 years from now) | |
| US10392406 | GENENTECH | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| US8987441 | GENENTECH | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Oct, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10633397 | GENENTECH | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| US11306106 | GENENTECH | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(11 years from now) | |
| US11925648 | GENENTECH | Solid dosage form having excellent stability |
Apr, 2041
(15 years from now) | |
| US9815835 | GENENTECH | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(4 years from now) | |
| US8927710 | GENENTECH | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(5 years from now) | |
| US11261198 | GENENTECH | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(12 years from now) | |
| US12064438 | GENENTECH | Pharmaceutical preparation excellent in light stability and dissolution property |
Oct, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
| M(M-187) | Dec 19, 2027 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage
XOFLUZA family patents
68. Zemdri patent expiration
Treatment: Method of using plazomicin to treat bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383596 | CIPLA | Antibacterial aminoglycoside analogs |
Jun, 2032
(6 years from now) | |
| US9688711 | CIPLA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| US8822424 | CIPLA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 25 June, 2022
Market Authorisation Date: 25 June, 2018
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
69. Zyvox patent expiration
Treatment: Treatment of microbial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514529 | PFIZER | Oxazolidinone tablet formulation |
Mar, 2021
(4 years ago) | |
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(5 years ago) | |
|
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(4 years ago) | |
| US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(11 years ago) | |
|
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(10 years ago) | |
|
US6514529 (Pediatric) | PFIZER | Oxazolidinone tablet formulation |
Sep, 2021
(4 years ago) | |
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Dosage: SOLUTION; TABLET; FOR SUSPENSION
How can I launch a generic of ZYVOX before it's drug patent expiration?
More Information on Dosage
ZYVOX family patents